TEL AVIV, Israel, September 22, 2016 /PRNewswire/ --
BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical stage
biopharmaceutical company dedicated to identifying, in-licensing
and developing promising therapeutic candidates, announced today
its corporate objectives at an ongoing investor breakfast meeting
at the Convene Conference Center near Grand Central in New York City. These objectives include
continued execution of advanced clinical studies for its lead
oncology platform, deepening of its existing strategic
collaborations with leading global pharma companies, focused
pipeline development into additional high-value markets, and
targeted milestones in line with its five-year corporate
vision.
As the Company looks to 2017, objectives include:
- Initiation and ramp up of several Phase 1b combination studies
of BL-8040 and Atezolizumab for multiple solid tumor indications
and AML in the framework of its Genentech immunotherapy
collaboration;
- Partial results in the first pancreatic immunotherapy Phase 2a
combination study of BL-8040 and KEYTRUDA® in the framework of its
Merck immunotherapy collaboration;
- Interim and final results from a Phase 2 study for BL-8040 in
stem cell mobilization;
- GRAS designation for BL-7010 as a food supplement, paving the
way for US partnering discussions;
- Additional skin lesion indications for BL-5010, including
potential partnering for entry and commercialization in the
US;
- Continued evaluation of innovative assets under the Novartis
strategic collaboration, resulting in the in-licensing of
additional promising new projects;
- New programs announced under the Company's iPharma joint
venture in China.
As BioLineRx looks to the future, it is also highlighting its
five-year strategic corporate objectives, including maintaining a
critical mass of advanced projects in development, alongside a
portfolio of revenue-generating assets. Active partnering,
licensing and business development programs remain on target,
including the potential to secure a significant out-licensing
transaction with a global pharmaceutical company, as well as the
execution of new strategic transactions as the opportunities
arise.
Philip Serlin, Chief Financial
and Operating Officer of BioLineRx, stated, "We are very excited
about our prospects ahead. We continue to build clinical evidence
in support of our therapeutic assets, which are validated by our
growing roster of programs and partnerships with leading industry
players such as Novartis, Merck and Genentech, bolstering our
access to cutting edge technologies and key opinion leaders. The
entire BioLineRx team is aligned, focused and committed to
delivering on our strategic corporate objectives. We look forward
to providing our investors with timely updates."
Additional topics for discussion at the ongoing BioLineRx
investor breakfast meeting include 1) an overview of BL-8040, the
Company's lead program in oncology, with an emphasis on the cancer
immunotherapy collaborations, and the development and
commercialization plans in stem-cell mobilization; and 2) a keynote
presentation by Dr. Manuel Hidalgo,
a world-renowned key opinion leader in pancreatic cancer and Chief
of the Division of Hematology-Oncology at Beth Israel Deaconess
Medical Center, an affiliate of Harvard
University in Boston.
BioLineRx is hosting a live webcast of the investor breakfast.
To access the webcast, please go to the breakfast event page on
BioLineRx's website. An audio replay of the meeting will also be
available for approximately three months following the meeting on
the breakfast event page.
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds,
primarily from academic institutions and biotech companies based in
Israel, develops them through
pre-clinical and/or clinical stages, and then partners with
pharmaceutical companies for advanced clinical development and/or
commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a
cancer therapy platform, which has successfully completed a Phase
2a study for relapsed/refractory AML, is in the midst of a Phase 2b
study as an AML consolidation treatment, and has recently initiated
a Phase 2 study in stem cell mobilization for allogeneic
transplantation; and BL-7010 for celiac disease and gluten
sensitivity, which has successfully completed a Phase 1/2 study. In
addition, BioLineRx has a strategic collaboration
with Novartis for the co-development of selected
Israeli-sourced novel drug candidates; a collaboration agreement
with MSD (known as Merck in the US and Canada) to run a Phase 2a study in pancreatic
cancer using the combination of BL-8040 and Merck's
KEYTRUDA®; and has recently signed a collaboration
agreement with Genentech, a member of the Roche Group, to
investigate the combination of BL-8040 and Genentech's Atezolizumab
in several Phase 1b studies for multiple solid tumor indications
and AML.
For additional information on BioLineRx, please visit the
Company's website at http://www.biolinerx.com, where you can review
the Company's SEC filings, press releases, announcements and
events. BioLineRx industry updates are also regularly updated on
Facebook, Twitter, and LinkedIn.
Various statements in this release concerning
BioLineRx's future expectations constitute
"forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements include words such as
"may," "expects,"
"anticipates,"
"believes," and
"intends," and describe opinions about
future events. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the actual results,
performance or achievements of BioLineRx to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Some of these risks
are: changes in relationships with collaborators; the impact of
competitive products and technological changes; risks relating to
the development of new products; and the ability to implement
technological improvements. These and other factors are more fully
discussed in the "Risk Factors" section
of BioLineRx's most recent annual report on Form 20-F
filed with the Securities and Exchange Commission on March 10, 2016. In addition, any forward-looking
statements represent BioLineRx's views only as of the
date of this release and should not be relied upon as representing
its views as of any subsequent date. BioLineRx does not assume any
obligation to update any forward-looking statements unless required
by law.
Contact:
PCG Advisory
Vivian Cervantes
Investor Relations
+1-212-554-5482
vivian@pcgadvisory.com
or
Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipihai5@gmail.com
SOURCE BioLineRx Ltd.